Visipaque - Iodixanol

Jo SH, Youn TJ, Koo BK, Park JS, Kang HJ, Cho YS, Chung WY, Joo GW, Chae IH, Choi DJ, Oh BH, Lee MM, Park YB, Kim HS Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography the recover study a randomized controlled trial. J Am Coll Cardiol 2006 48 924-930. [Pg.83]

Sutton AG, Ashton VJ, Campbell PG, Price DJ, Hall JA, de Beider MA. A randomized prospective trial of ioxaglate 320 (Hexabrix) vs. iodixanol 320 (Visipaque) in patients undergoing percutaneous coronary intervention. Catheter Cardiovasc Interv 2002 57(3) 346-52. [Pg.1887]

Bertrand ME, Esplugas E, Piessens J, Rasch W [Visipaque in Percutaneous Transluminal Coronary Angioplasty VIP.] Trial Investigators. Influence of a nonionic, iso-osmolar contrast medium (iodixanol) versus an ionic, low-osmolar contrast medium (ioxaglate) on major adverse cardiac events in patients undergoing percutaneous transluminal coronary angioplasty a multicenter, randomized, doubleblind study. Circulation 2000 101(2) 131-6. [Pg.1887]

Rudnick MR, Davidson C, Laskey W, Stafford JL, Sherwin PF Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease the visipaque angiography/ interventions with laboratory outcomes in renal insufficiency (VALOR) trial. Am Heart J 2008 156 776-782. [Pg.83]

Big Chemical Encyclopedia